期刊文献+

单克隆抗体非临床免疫毒性研究的考虑要点 被引量:1

Considerations on nonclinical studies for immunotoxicity of monoclonal antibodies
原文传递
导出
摘要 大多数单克隆抗体可诱导免疫反应,免疫毒性是免疫调节类单克隆抗体主要担心的毒性反应。本文总结了单克隆抗体的免疫毒性特征、免疫毒性的相关因素,非临床免疫毒性研究与评价的考虑要点。建议在临床前研究阶段应根据单克隆抗体的作用特征,对药物的免疫毒性进行逐步分层研究,当需要追加试验时,应追加研究;还应体内外研究相结合,动物种属和人体离体细胞相结合,多途径进行研究。 Most monoclonal antibodies (mAbs) can induce immune responses. For immunomodulatory mAbs, immunotoxicity is themajor toxicity. This article summarizes the characteristics of immunotoxicity, the factors associated with immunotoxicity, and thegeneral considerations of nonclinical studies and evaluations. Before the clinical trials, comprehensive nonclinical studies onimmunotoxicityshould be step by step conductedbased on mAbs' characteristics. If needed, some additional studies should beconducted. Attention should be paid to combination of in vivo and in vitro studies, combination of animal species and humanex vivocells, and multiple approaches for studies.
出处 《药物评价研究》 CAS 2017年第9期1248-1253,共6页 Drug Evaluation Research
关键词 单克隆抗体 免疫毒性 免疫原性 非临床研究 mAbs immunotoxicity immunogenicity nonclinical study
  • 相关文献

参考文献1

二级参考文献11

  • 1吕秋军.生物技术药物免疫原性的评价及面临的挑战[J].中国新药杂志,2007,16(3):181-188. 被引量:24
  • 2生物类似药研究与评价技术指导原则(试行)[S].2015.
  • 3CHOW S. Biosimilars :Design and Analysis of Follow-on Biologics [M]. Boca Raton :CRC Press, 2014,53-75.
  • 4BENNETT C L, CHEN B, HERMANSON T, et al. Regulatory and clinical considerations for biosimilar oncology drugs [ J ]. Lan- cet Oncol, 2014,15 : e594-605.
  • 5NENCINI F, PRATESI S, PETRONI G,et al. Assays and strate- gies for immunogenicity assessment of biological agents [ J ]. Drug Dev Res,2014, 75:S4-S6.
  • 6CAI X Y, THOMAS J, CULLEN C,et al. Challenges of develo- ping and validating immunogenicity assays to support comparabili- ty studies for biosimilar drug development [ J ]. Bioanalysis, 2012, 4(17) :2169-2177.
  • 7CHAMBERLAIN P. Assessing immunogenicity of biosimilar ther- apeutic monoclonal antibodies: regulatory and bioanalytical con- siderations[ J]. Bioanalysis,2013,5 (5) :561-574.
  • 8CHOY E, JACOBS I A. Biosimilar Safety Considerations in Clini- cal Practice[ J]. Sernin Oncol, 2014,41 :S3-S14.
  • 9EBBERS H C, CROW S A, VULTO A G,et al. Interehangeability, immunogenicity and biosimilars [ J]. Nat Biotec, 2012,30 (12) :1186-1190.
  • 10PRUGNAUD J L, TROUVIN J H. Biosimilars-A New Generation of Biologics [ M ]. Pairs : Springer-Verlag France, 2013:37-46.

共引文献18

同被引文献14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部